Contact Us
Drug Search Results
More Filters [+]

Losmapimod

Alternative Names: losmapimod, gw856553, gw856553x, gs856553
Latest Update: 2024-09-13
Latest Update Note: News Article

Product Description

Mechanisms of Action: MAPK Inhibitor,Immunomodulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Fast Track - Muscular Dystrophies|Muscular Dystrophy, Facioscapulohumeral
Orphan Drug - Muscular Dystrophies|Muscular Dystrophy, Facioscapulohumeral *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Losmapimod

Countries in Clinic: Canada, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States

Active Clinical Trial Count: 8

Highest Development Phases

Phase 3: Muscular Dystrophy, Facioscapulohumeral

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
1821-FSH-301

P3

Unknown Status

Muscular Dystrophy, Facioscapulohumeral

2027-05-31

FIS-001-2019

P2

Unknown Status

Muscular Dystrophy, Facioscapulohumeral

2026-01-01

FIS-002-2019

P2

Unknown Status

Muscular Dystrophy, Facioscapulohumeral

2025-10-31

FSHD

P2

Active, not recruiting

Muscular Dystrophy, Facioscapulohumeral

2025-10-01

24%

Recent News Events

Date

Type

Title

09/13/2024

News Article

 Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/12/2024

News Article

 Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

09/12/2024

News Article

 FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

08/27/2024

News Article

 Fulcrum Therapeutics to Participate in Upcoming September Conferences

05/01/2024

PubMed

 Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.

04/01/2024

PubMed

 Vitamin D3 inhibits p38 MAPK and senescence-associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing.

09/30/2023

PubMed

 Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions